Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510626 · ClinicalTrials.gov registry record · Phase 1
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01510626: Completed Phase 1 study, sponsored by Stanford University.
NCT01510626 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01510626, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.
Interventions
- DRUG Omalizumab
- DIETARY_SUPPLEMENT Food proteins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01510626
The ClinicalTrials.gov registry entry for NCT01510626 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omalizumab is the first listed.
NCT01510626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01510626 about?
NCT01510626 is a clinical study titled "Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center". The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food aller...
What is the current status of trial NCT01510626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01510626?
The interventions under investigation include: Omalizumab (DRUG), Food proteins (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01510626?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.